Stockscreener 앱 받기
0.33%
시간 외 거래:
전일 마감가:
$27.32
열려 있는:
$27.29
하루 거래량:
47.90M
Relative Volume:
1.02
시가총액:
$155.86B
수익:
$62.58B
순이익/손실:
$7.79B
주가수익비율:
20.23
EPS:
1.3551
순현금흐름:
$9.08B
1주 성능:
+2.05%
1개월 성능:
+2.05%
6개월 성능:
+14.07%
1년 성능:
+4.58%
1일 변동 폭
$27.25
$27.73
1주일 범위
$26.52
$27.76
52주 변동 폭
$20.91
$27.94
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.41 | 155.35B | 62.58B | 7.79B | 9.08B | 1.3551 |
|
LLY
Lilly Eli Co
|
917.50 | 819.81B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.60 | 571.52B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
206.23 | 368.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
188.93 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
148.19 | 285.86B | 54.72B | 14.02B | 15.32B | 7.1855 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 업그레이드 | Argus | Hold → Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Underperform |
| 2026-02-20 | 개시 | Barclays | Underweight |
| 2026-02-12 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Globe and Mail
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Motley Fool
Does Positive TALAPRO‑3 and FOURLIGHT‑1 Data Reframe Pfizer’s Oncology Story And Investment Case (PFE)? - simplywall.st
Pfizer to seek earlier indication for Talzenna combo - The Pharma Letter
Why Is Pfizer Stock Gaining Thursday?Pfizer (NYSE:PFE) - Benzinga
Self-represented worker ordered to pay $10K after abandoning motion to disqualify Pfizer’s counsel - HR Law Canada
Pfizer Among World’s Most Ethical Companies for 5th Straight Year - Pfizer
Pfizer (PFE) Achieves Key Milestone with Prostate Cancer Drug Tr - GuruFocus
Swiss Life Asset Management Ltd Decreases Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Reports Positive Results in Prostate Cancer Study - marketscreener.com
Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication - Seeking Alpha
Wilmington Savings Fund Society FSB Sells 75,143 Shares of Pfizer Inc. $PFE - MarketBeat
Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Alto Neuroscience, Inc. (ANRO) and Pfizer (PFE) - The Globe and Mail
CIBC Bancorp USA Inc. Invests $20.07 Million in Pfizer Inc. $PFE - MarketBeat
AIA Group Ltd Has $12.31 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Achmea Investment Management B.V. Acquires 201,826 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer's Oncology Pipeline Gains Momentum with Promising Breast Cancer Trial Data - AD HOC NEWS
Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels - Yahoo Finance
Pfizer (NYSE:PFE) Enhances Value Proposition Across Russell 1000 Healthcare Sector - Kalkine Media
Pfizer Advances Early PF-07328948 Liver Study, Adding Quiet Support to PFE’s Pipeline Story - TipRanks
Pfizer Ends Early-Stage Melanoma Study, Trimming One Oncology Bet But Not the Broader Pipeline - TipRanks
Pharma Stocks Analysis 2026: Pfizer & Novo Nordisk Rebound, Exelixis GrowthNews and Statistics - IndexBox
Lucid Group Appoints Former Pfizer R&D Leader Rod MacKenzie, CMG, PhD, as Board Chair to Drive Next Phase of Global Growth and Innovation - PR Newswire
Pfizer Inc (NYSE:PFE) Moves with S&P 500 Amid Pipeline Updates - Kalkine Media
Pfizer: I'm Still Expecting A Massive Rebound (NYSE:PFE) - Seeking Alpha
Pfizer Phase 2 Wins Reshape Growth Story In Oncology And Immunology - simplywall.st
Danske Bank A S Acquires Shares of 3,190,647 Pfizer Inc. $PFE - MarketBeat
Morgan Stanley Maintains Positive on Pfizer Inc. (PFE) March 2026 - Meyka
Captrust Financial Advisors Cuts Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer, Roche Looking Beyond Simple Licensing In China Deals - Citeline News & Insights
Jim Cramer Notes Pfizer (PFE) Has “Got a Lot of Stuff in the Pipeline” - Insider Monkey
Pfizer (NYSE:PFE) Trading 3.2% Higher Following Analyst Upgrade - MarketBeat
Pfizer Finds Lucky Clover In Phase II Atirmociclib Trial - Citeline News & Insights
Pfizer Reports Positive Mid-Stage Breast Cancer Trial Results - GuruFocus
Pfizer Inc Stock (PFE) Moved Up by 3.89% on Mar 17: What Investors Need To Know - TradingKey
+3.04% for Pfizer stock — Strong R&D focus and positive drug news lift shares - Traders Union
What triggered Pfizer shares' latest price surge - Traders Union
HSBC Maintains Buy Rating on Pfizer (PFE) with Raised Price Targ - GuruFocus
Pfizer Reports Positive Phase 2 Results for Breast Cancer Treatment Candidate - geneonline.com
Pfizer’s Ibrance successor moves forward with new study data - BioPharma Dive
Pfizer Touts Promising Survival Data Without Worsening For Advanced Breast Cancer Patients - Benzinga
Morgan Stanley reiterates Pfizer stock rating on positive trial data - Investing.com
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Narcissu Market Set for Dynamic Boom as Key Players Pfizer • Johnson & Johnson • Merck & Co. • Amgen - openPR.com
Pfizer (PFE) Reports Positive Mid-Stage Trial Results for Breast Cancer Therapy - GuruFocus
Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial - marketscreener.com
National Bank of Canada FI Decreases Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer (PFE) Reveals Promising Phase 2 Study Results for Atirmoc - GuruFocus
Pfizer Inc. Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib in Second-Line Metastatic Breast Cancer - marketscreener.com
Pfizer posts mid-stage trial win for breast cancer drug (PFE) - Seeking Alpha
Federal Judge Flags Legal Flaws In RFK Jr.'s Vaccine Overhaul - Benzinga
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.99%
자본화:
|
볼륨(24시간):